Trials / Terminated
TerminatedNCT05262101
Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma
Single-arm, Open-label, Multicenter Phase Ib Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open-label, multicenter Phase Ib clinical trial evaluating TQB2858 injection in the treatment of advanced high-grade sarcoma. To evaluate the preliminary efficacy and safety of TQB2858 injection in patients with advanced high-grade sarcoma, and to explore the relevant biomarkers of TQB2858 injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2858 injection | TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody. |
Timeline
- Start date
- 2022-05-09
- Primary completion
- 2023-06-28
- Completion
- 2023-11-30
- First posted
- 2022-03-02
- Last updated
- 2024-01-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05262101. Inclusion in this directory is not an endorsement.